Abcuro, a clinical-stage biotechnology company that develops first-in-class immunotherapies for the treatment of autoimmune diseases and cancer, was at an inflection point. With success on several assets in the pipeline, including ABC008 which has FDA Orphan Drug designation, they were in search of leadership that could help see the company through its next phase of evolution and they placed their trust in Stevenson.
Our mission was to find a commercially oriented CEO with a track record of scaling an organization while also finding a Chief Medical Officer who could lead their programs through to commercialization. Through our extensive network, Stevenson was able to do these searches in parallel finding two leaders who complement one another. In a highly competitive market, Stevenson was able to appoint both executives in under six months. Both with strong leadership skills readying them to tackle the anticipated challenges that lie ahead and take the organization to the next level.